These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23375793)

  • 21. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
    Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San-Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; SanMiguel JF; Del Cañizo C; Blanco B
    Br J Haematol; 2016 Jun; 173(5):754-68. PubMed ID: 26914848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia.
    Hadley G; Beard DJ; Alexopoulou Z; Sutherland BA; Buchan AM
    Neurosci Lett; 2019 Jul; 706():223-230. PubMed ID: 31100427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
    Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
    J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.
    Asahina H; Nokihara H; Yamamoto N; Yamada Y; Tamura Y; Honda K; Seki Y; Tanabe Y; Shimada H; Shi X; Tamura T
    Invest New Drugs; 2013 Jun; 31(3):677-84. PubMed ID: 22843211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect.
    Sousa-Victor P; García-Prat L; Muñoz-Cánoves P
    Oncotarget; 2015 Sep; 6(27):23052-4. PubMed ID: 26375366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
    Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
    Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
    Eyre TA; Collins GP; Goldstone AH; Cwynarski K
    Br J Haematol; 2014 Aug; 166(3):336-51. PubMed ID: 24842496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.
    Naing A; Aghajanian C; Raymond E; Olmos D; Schwartz G; Oelmann E; Grinsted L; Burke W; Taylor R; Kaye S; Kurzrock R; Banerji U
    Br J Cancer; 2012 Sep; 107(7):1093-9. PubMed ID: 22935583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of mTOR Inhibitors in Kidney Disease.
    Kajiwara M; Masuda S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.
    Diez H; Benitez MJ; Fernandez S; Torres-Aleman I; Garrido JJ; Wandosell F
    Biochim Biophys Acta; 2016 Nov; 1863(11):2574-2583. PubMed ID: 27421985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.